Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study
In the treatment of mHSPC, DARO + ADT was associated with significant improvement of clinical outcomes <i>versus</i> AAP + ADT, while their safety is comparable.
Authors
- Zheng Yang (ORCID: https://orcid.org/0000-0002-6044-3298)
- Fang Zhou (ORCID: https://orcid.org/0000-0001-5102-5409)
- Dong Wang (ORCID: https://orcid.org/0000-0002-5245-3074)
- Jinze Zhang (ORCID: https://orcid.org/0009-0009-4574-3848)
- Yu Nie (ORCID: https://orcid.org/0000-0002-8744-0046)
- Céline Gu (ORCID: https://orcid.org/0009-0008-1700-301X)
- Guopeng Wang
- Wenjia Di
- Yunlin Feng (ORCID: https://orcid.org/0000-0003-4393-6661)
- Zhang Yong-liang (ORCID: https://orcid.org/0000-0002-1937-4219)
- Jingzhi Tian
- Shangqing Ren
- Ting Hu (ORCID: https://orcid.org/0009-0001-4802-9086)
- Bohan Luo
Institutions
- University of Electronic Science and Technology of China (CN)
- Southwest Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.3389/fphar.2025.1608339
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00